SCHEMBL4024552

SCHEMBL4024552

CC(C)(C)Oc1ccc(C(=O)Nc2ccc(CC(=O)NO)cc2)cc1OC(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 3/20 0.53
SMN1; SMN2 Q16637 4/20 0.48
MAPT P10636 4/20 0.48
LMNA P02545 3/20 0.48
RAB9A P51151 2/20 0.47
NPC1 O15118 2/20 0.47
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 2/20 0.46
TP53 P04637 1/20 0.46
POLB P06746 2/20 0.45
HTT P42858 1/20 0.45
ROCK2 O75116 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4026426 0.84 MEN1 (0.61) NR1H4SMN1; SMN2MAPTLMNARAB9A
SCHEMBL4020377 0.82 MAPT (0.57) NR1H4SMN1; SMN2MAPTLMNARAB9A
SCHEMBL4020386 0.82 MAPT (0.59) SMN1; SMN2MAPTLMNARAB9ANPC1
SCHEMBL4024140 0.80 HDAC1 (0.57) NR1H4SMN1; SMN2MAPTLMNARAB9A
SCHEMBL4020644 0.79 HDAC1 (0.58) SMN1; SMN2MAPTLMNAKDM4EHTT
SCHEMBL4659050 0.78 NR1H4 (0.74) NR1H4SMN1; SMN2MAPTLMNARAB9A
SCHEMBL4656274 0.77 NPC1 (0.71) NR1H4SMN1; SMN2MAPTRAB9ANPC1
SCHEMBL4180097 0.77 MEN1 (0.45) NR1H4SMN1; SMN2MAPTLMNARAB9A
SCHEMBL5438741 0.75 RAB9A (0.67) NR1H4SMN1; SMN2MAPTRAB9ANPC1
SCHEMBL4659243 0.75 HDAC3 (0.57) NR1H4SMN1; SMN2MAPTLMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1874722-B1 HYDROXAMIC ACID DERIVATIVES AND THE PREPARATION METHOD THEREOF AMOREPACIFIC CORP (KR) 2015-04-08 EP claimed
US-7485750-B2 Hydroxamic acid derivatives and the preparation method thereof AMOREPACIFIC CORPORATION (KR) 2009-02-03 US claimed
US-20080242730-A1 Hydroxamic Acid Derivatives and the Preparation Method Thereof AMOREPACIFIC CORPORATION (KR) 2008-10-02 US claimed
EP-1874722-A1 HYDROXAMIC ACID DERIVATIVES AND THE PREPARATION METHOD THEREOF Amorepacific Corporation (KR) 2008-01-09 EP claimed
WO-2006118380-A1 HYDROXAMIC ACID DERIVATIVES AND THE PREPARATION METHOD THEREOF AMOREPACIFIC CORPORATION (KR) 2006-11-09 WO claimed
EP-1874722-B1 HYDROXAMIC ACID DERIVATIVES AND THE PREPARATION METHOD THEREOF AMOREPACIFIC CORP (KR) 2015-04-08 EP disclosed
US-7485750-B2 Hydroxamic acid derivatives and the preparation method thereof AMOREPACIFIC CORPORATION (KR) 2009-02-03 US disclosed
US-20080242730-A1 Hydroxamic Acid Derivatives and the Preparation Method Thereof AMOREPACIFIC CORPORATION (KR) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242730-A1 Hydroxamic Acid Derivatives and the Preparation Method Thereof COL14A1, CUTA, COL2A1 NR1H4 4352/4885SMN1; SMN2 4505/4885MAPT 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.